Pharmacometabolomic signature links simvastatin therapy and insulin resistance: an addition to the topical collection “Recent Advances in Pharmacometabolomics: Enabling Tools for Precision Medicine”

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Metabolomics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11306-017-1190-2PMID 29732238PMCID PMC5931366
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Branched-Chain Amino Acid-Related Metabolic Signature Characterizes Obese Adolescents with Non-Alcoholic Fatty Liver Disease

  2017cited by this paper
• National survey of the management of Diabetic Ketoacidosis (DKA) in the UK in 2014

  2016cited by this paper
• Intratracheal instillation of pravastatin for the treatment of murine allergic asthma: a lung-targeted approach to deliver statins

  2015cited by this paper
• N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution

  2015cited by this paper
• Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine

  2015cited by this paper
• Preventing Diabetic Ketoacidosis.

  2015cited by this paper
• MetaboAnalyst 3.0—making metabolomics more meaningful

  2015cited by this paper
• Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.

  2015cited by this paper
• Gene expression profile of high-fat diet-fed C57BL/6J mice: in search of potential role of azelaic acid

  2015cited by this paper
• Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis

  2014cited by this paper
• Statin therapy is associated with the development of new‐onset diabetes after transplantation in liver recipients with high fasting plasma glucose levels

  2014cited by this paper
• Statin Treatment, New-Onset Diabetes, and Other Adverse Effects: A Systematic Review

  2014cited by this paper
• Hydroxylamine enhances glucose uptake in C2C12 skeletal muscle cells through the activation of insulin receptor substrate 1.

  2014cited by this paper
• Statin treatment and new-onset diabetes: a review of proposed mechanisms.

  2014cited by this paper
• Statin therapy and related risk of new-onset type 2 diabetes mellitus.

  2014cited by this paper
• Risk of new-onset diabetes mellitus versus reduction in cardiovascular events with statin therapy.

  2014cited by this paper
• Pharmacometabolomics: Implications for Clinical Pharmacology and Systems Pharmacology

  2014influential reference
• Pharmacometabolomics of Statin Response

  2013cited by this paper
• 2-Aminoadipic acid is a biomarker for diabetes risk.

  2013cited by this paper
• Efficacy of azelaic acid on hepatic key enzymes of carbohydrate metabolism in high fat diet induced type 2 diabetic mice.

  2013influential reference
• Metabolomics Reveals Amino Acids Contribute to Variation in Response to Simvastatin Treatment

  2012influential reference
• Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.

  2012cited by this paper
• Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users.

  2012cited by this paper
• MetaboAnalyst 2.0—a comprehensive server for metabolomic data analysis

  2012cited by this paper
• Identification of fever and vaccine-associated gene interaction networks using ontology-based literature mining

  2012cited by this paper
• Metabolic Signatures of Insulin Resistance in 7,098 Young Adults

  2012cited by this paper
• Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

  2011cited by this paper
• Metabolite profiles and the risk of developing diabetes

  2011cited by this paper
• Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment

  2011cited by this paper
• Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs.

  2010cited by this paper
• Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study

  2010cited by this paper
• Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

  2010cited by this paper
• Major diet-drug interactions affecting the kinetic characteristics and hypolipidaemic properties of statins.

  2010cited by this paper
• Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis.

  2010cited by this paper
• Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics.

  2010cited by this paper
• Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men

  2010cited by this paper
• FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry.

  2009cited by this paper
• Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond.

  2009cited by this paper
• A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance.

  2009cited by this paper
• MetaboAnalyst: a web server for metabolomic data analysis and interpretation

  2009cited by this paper
• Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

  2009cited by this paper
• Partial Correlation Estimation by Joint Sparse Regression Models

  2008cited by this paper
• Pharmacogenomics of statin response.

  2008cited by this paper
• Metabolomics: a global biochemical approach to drug response and disease.

  2008cited by this paper
• Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

  2008cited by this paper
• Statins: a new insight into their mechanisms of action and consequent pleiotropic effects.

  2007cited by this paper
• Pharmacogenomics of statin response

  2007cited by this paper
• Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study.

  2006cited by this paper
• Diabetic ketoacidosis.

  2005cited by this paper
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

  2004cited by this paper
• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

  2004cited by this paper
• The positive false discovery rate: a Bayesian interpretation and the q-value

  2003cited by this paper
• Influence of nitric oxide synthase inhibition, nitric oxide and hydroperoxide on insulin release induced by various secretagogues

  1995cited by this paper
• Hydroxylamine is a vasorelaxant and a possible intermediate in the oxidative conversion of L-arginine to nitric oxide.

  1989cited by this paper
• 4 Branched-Chain Ketoacid Dehydrogenase

  1987cited by this paper
• Aminomalonic acid: identification in Escherichia coli and atherosclerotic plaque.

  1984cited by this paper
• Purification and characterization of N-methylalanine dehydrogenase.

  1975cited by this paper
• Pacific Symposium on Biocomputing 12:169-180(2007) SETUP X – A PUBLIC STUDY DESIGN DATABASE FOR METABOLOMIC PROJECTS

  year unknowncited by this paper

• Protective Effects of Lotus Seedpod Extract on Hepatic Lipid and Glucose Metabolism via AMPK-Associated Mechanisms in a Mouse Model of Metabolic Syndrome and Oleic Acid-Induced HepG2 Cells

  2025cites this paper
• Effects of Nicotine on SH-SY5Y Cells: An NMR-Based Metabolomic Study

  2025cites this paper
• Identification of endophenotypes supporting outcome prediction in hemodialysis patients based on mechanistic markers of statin treatment

  2024cites this paper
• Pharmacokinetics in Pharmacometabolomics: Towards Personalized Medication

  2023cites this paper
• Pharmacometabolomics for the Study of Lipid-Lowering Therapies: Opportunities and Challenges

  2023cites this paper
• Pharmacometabolomics-Based Translational Biomarkers: How to Navigate the Data Ocean

  2022cites this paper
• Whole-body metabolic modelling predicts isoleucine dependency of SARS-CoV-2 replication

  2022cites this paper
• UPLC-MS-Based Serum Metabolic Profiling Reveals Potential Biomarkers for Predicting Propofol Responsiveness in Females.

  2021cites this paper
• Cell adhesion molecule-mediated therapeutic strategies in atherosclerosis: From a biological basis and molecular mechanism to drug delivery nanosystems.

  2021cites this paper
• Identification of biomarkers to diagnose diseases and find adverse drug reactions by metabolomics.

  2020cites this paper
• Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine

  2020cites this paper
• Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug–metabolite atlas

  2020cites this paper
• Pharmacometabolomics applied to zonisamide pharmacokinetic parameter prediction

  2018cites this paper
• Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy

  2018cites this paper
• Pharmacometabolomics and Precision Medicine Special Issue Editorial

  2017cites this paper